On September 18, 2023 the Board of Directors of Fresh Tracks Therapeutics, Inc. terminated Andrew D. Sklawer, the Company?s President and Chief Executive Officer, without cause, effective October 2, 2023. In addition, on September 18, 2023, each of the members of the Board (Reginald L. Hardy, Gary A. Lyons and Vijay B. Samant) informed the Company that he will resign from the Board, effective October 2, 2023. Messrs.

Hardy?s, Lyons? and Samant?s decisions to resign relate to the proposed liquidation and dissolution of the Company and are not the result of any disagreement on any matter relating to the operations, policies or practices of the Company. Also, on September 18, 2023, the Board appointed Albert N. Marchio, II, the Company?s current Chief Financial Officer, as the Company?s new Chief Executive Officer, Chief Financial Officer, and Secretary, as well as a director and Chairman of the Board, in each case effective October 2, 2023.

As such, Mr. Marchio will become the Company?s principal executive officer and will remain the Company?s principal financial officer. Mr. Marchio was appointed the Company?s Chief Financial Officer effective December 1, 2020. He has been with Danforth Advisors since May 2019, providing financial consulting services on a project/interim basis for public (CytomX Therapeutics, Inc. and various private life sciences companies.

Previously, Mr. Marchio served in various finance and accounting roles at Edge Therapeutics, Inc. (now known as PDS Biotechnology Corporation), a clinical-stage biopharmaceutical company, including Chief Accounting and Administrative Officer from October 2016 to November 2018, Interim Chief Financial Officer from March 2017 to October 2017, Chief Accounting and Operations Officer from March 2014 to October 2016, and Chief Financial Officer from December 2011 through March 2014.